EICHORCondition: Breast Cancer · Sponsor: Adrienne G. Waks
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States | — |
| Johns Hopkins University | Baltimore, Maryland, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | — |
| Montefiore Medical Center | The Bronx, New York, United States | — |
| University of Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | — |
| Duke University Medical Center | Durham, North Carolina, United States | — |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03414658